-+ 0.00%
-+ 0.00%
-+ 0.00%

Here's What I'm Planning With My Eli Lilly Position

The Motley Fool·10/21/2026 03:46:12
Listen to the news

Business is booming, and the pipeline of new treatments is robust.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

*Stock prices used were the afternoon prices of Oct. 18, 2026. The video was published on Oct. 20, 2026.

Parkev Tatevosian, CFA has positions in Eli Lilly. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.